The latest announcement is out from Purple Biotech ( (PPBT) ).
On April 30, 2025, Purple Biotech Ltd. announced the final data from its Phase 2 study of CM24 in pancreatic cancer patients, presented at the AACR 2025 Annual Meeting. The study demonstrated statistically significant efficacy in biomarker-enriched subgroups, with notable reductions in the risk of death and progression in patients with specific biomarker profiles. The findings suggest that CM24 could be positioned as a therapy targeting CEACAM1 in cancers with large unmet needs, and the identified biomarkers will guide patient selection in an upcoming Phase 2b study.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, with CM24 being a humanized monoclonal antibody targeting CEACAM1, a novel target for treating multiple cancer indications.
YTD Price Performance: -42.27%
Average Trading Volume: 25,770
Technical Sentiment Signal: Buy
Current Market Cap: $6.74M
Find detailed analytics on PPBT stock on TipRanks’ Stock Analysis page.